On its alleged day of reckoning shares of Herbalife (NYSE:HLF) instead saw 25% gains. Confused? What happened here was a classic case of over-promising and under-delivering.

Bill Ackman, whose hedge fund Pershing Square has a massive short position on Herbalife, promised to deal the company a deathblow in a presentation today. That deathblow wasn't even glancing, despite spending $50 million on an investigation to uncover what Ackman sees as a fraudulent business model. Of course with government investigations pending, it remains too early for Herbalife bulls, including rival hedge fund titan Carl Icahn, to declare victory.

In this video Motley Fool health care analysts David Williamson and Michael Douglass, discuss Ackman's would be "death blow" dealing presentation and how most investors should approach this battleground stock.

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has the following options: long January 2016 $57 calls on Herbalife. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.